ARTCLINE‘s vision is to become the leading biotech company for immune cell based extracorporeal sepsis therapy.
Currently, we are focused on the clinical trials and the further development of our ARTICE® Therapy for the treatment of bacterial sepsis.
Sepsis or septic shock are main causes of death, especially in the intensive care units. In addition, high therapy costs are associated with sepsis due to high therapeutic and diagnostic efforts but also the length of stay in the hospital.
ARTCLINE develops a novel immune cell-based extracorporeal sepsis therapy ARTICE® for patients and medical practitioners worldwide. Effectiveness, safety and ease of use are the most important attributes of our therapy.
Our experience in the field of sepsis diagnosis and therapy helps us to accomplish our vision. Together with clinical experts and our partners, we will continue to identify immunological causes of and interactions in sepsis.
We, the founders, and the team of ARTCLINE have been successfully involved in the transfer of medical inventions from university research to industrial applications. We have an extensive network and many years of experience in the development of biopharmaceuticals and medical devices.
It all started at the Nephrology section of the University Medical Center Rostock. Already in 1998, the first attempts were initiated to develop a sepsis therapy system. In the early year’s successful treatments in rats and pigs were performed and published. The first clinical phase I/II study in humans was initiated in 2003. 2007, ARTCLINE was founded due to the encouraging results.
